Agencies: Media sources reported a short while ago that Pfizer has announced obtaining a global license for treating coronavirus.

The British newspaper "Daily Mail" revealed that the U.S. Food and Drug Administration "FDA" will approve the Pfizer booster dose for all American adults before the advisory committee meeting.

The newspaper said that the company submitted data to regulators last week in an attempt to obtain authorization for all Americans aged 18 and older.

Earlier, the head of the American pharmaceutical company Pfizer in the United Kingdom, Ben Osborne, said that its antiviral pills for treating the novel coronavirus (COVID-19) – if approved – will be available by early next year.

Osborne said – in exclusive statements to the British channel (Sky News) – that "following interim trial results, the company is working at a real pace with drug regulatory authorities worldwide, especially here in the UK with the Medicines and Healthcare products Regulatory Agency."
He added, "We expect to be registered in the near future – within the coming weeks – and then I hope, subject to the approvals granted, that we may see this drug available very early in 2022."

Last week, the American pharmaceutical company announced that the pills showed an 89% reduction in the risk of hospitalization or death due to coronavirus infection. The interim trial results of the drug, published last week, were based on a study of 775 adults.